atezolizumabbevacizumabFAP-IL2vSimlukafusp alfametastatic renal cell carcinoma (mRCC)mRCC
…uced vessel density.Conclusion The combination of FAP-IL2v plus atezolizumab with or without bevacizumab was consistent with the known safet…
1articles mentioning drugs
7drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: FAP-IL2v ×
FAP-IL2v
This drug is selected. Its supporting articles are shown below.